Shanghai - Delayed Quote CNY

Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS)

13.52
+0.50
+(3.84%)
At close: 3:00:04 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
522,771.29
417,804.70
411,363.85
244,219.27
255,709.51
Cost of Revenue
209,566.04
188,291.31
221,336.17
139,445.95
170,837.16
Gross Profit
313,205.26
229,513.39
190,027.68
104,773.32
84,872.35
Operating Expense
372,263.21
336,149.81
258,443.50
218,983.69
132,533.66
Operating Income
-59,057.96
-106,636.42
-68,415.82
-114,210.38
-47,661.31
Net Non Operating Interest Income Expense
-12,995.32
-12,963.63
-10,354.80
-1,281.04
2,355.90
Pretax Income
-117,552.59
-165,997.02
-92,085
-142,384.63
-42,274.38
Tax Provision
-17,934.37
-27,161.93
-16,015.46
-18,291.33
-12,288.76
Net Income Common Stockholders
-112,015.43
-141,204.29
-76,069.54
-124,093.30
-29,985.62
Basic EPS
-0.27
-0.34
-0.18
-0.30
-0.07
Diluted EPS
-0.27
-0.34
-0.18
-0.30
-0.07
Basic Average Shares
399,303.35
415,306.75
422,608.55
413,644.32
428,366.02
Diluted Average Shares
399,303.35
415,306.75
422,608.55
413,644.32
428,366.02
Total Operating Income as Reported
-115,777.14
-164,465.38
-92,047.92
-142,074.09
-43,837.17
Total Expenses
581,829.25
524,441.12
479,779.67
358,429.65
303,370.82
Net Income from Continuing & Discontinued Operation
-112,015.43
-141,204.29
-76,069.54
-124,093.30
-29,985.62
Normalized Income
-75,657.08
-97,842.70
-54,765.96
-94,102.10
-25,650.54
Interest Income
2,832.46
2,523.35
1,488.73
2,724.84
2,691.09
Interest Expense
15,710.25
15,360.25
11,763.79
3,918.40
246.09
Net Interest Income
-12,995.32
-12,963.63
-10,354.80
-1,281.04
2,355.90
EBIT
-101,842.34
-150,636.77
-80,321.21
-138,466.22
-42,028.30
EBITDA
-101,842.34
-97,464.86
-35,218.77
-100,612.89
-11,814.63
Reconciled Cost of Revenue
209,566.04
188,291.31
221,336.17
139,445.95
170,837.16
Reconciled Depreciation
--
53,171.91
45,102.44
37,853.33
30,213.67
Net Income from Continuing Operation Net Minority Interest
-112,015.43
-141,204.29
-76,069.54
-124,093.30
-29,985.62
Total Unusual Items Excluding Goodwill
-42,903.98
-51,844.93
-25,788.78
-34,411.89
-6,111.69
Total Unusual Items
-42,903.98
-51,844.93
-25,788.78
-34,411.89
-6,111.69
Normalized EBITDA
-58,938.36
-45,619.93
-9,430
-66,201
-5,702.94
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-6,545.63
-8,483.34
-4,485.19
-4,420.70
-1,776.61
12/31/2021 - 7/20/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

688222.SS HitGen Inc.
16.87
-0.82%
 
IVBIY Innovent Biologics Inc.
29.00
+11.07%
 
WXIBF WuXi Biologics (Cayman) Inc.
3.2000
0.00%
 
IVBXF Innovent Biologics, Inc.
9.30
-2.11%
 
196170.KQ ALTEOGEN Inc.
368,500.00
-3.28%
 
WXXWY WuXi Biologics (Cayman) Inc.
6.26
-0.63%
 
AKESF Akeso, Inc.
10.50
+0.72%
 
ATNF 180 Life Sciences Corp.
1.0501
+0.01%
 
VINC Vincerx Pharma, Inc.
0.0503
-6.94%
 
OSRH OSR Holdings, Inc.
1.4100
+0.71%